Evoke Pharma receives favorable response letter

The Food and Drug Administration issued a favorable response letter to Evoke Pharma (Nasdaq: EVOK) for its proposed pediatric study plan for EVK-001 sending the stock price soaring 99 cents to $5.62.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.